A new study identified a set of 140 genes that may help predict enhanced disease-free survival in patients with non-small cell lung cancer (NSCLC) treated with a combination of immunotherapy and low-dose radiation. The results, ...
Feb 23, 2024
0
29
A novel liquid biopsy test may help determine which patients with non-small cell lung cancer that has spread beyond the lungs are most likely to benefit from targeted, high-dose radiation, rather than drug-based therapy, ...
Oct 2, 2023
0
19
In an international study co-led by UCLA, scientists have shown that a new targeted therapy drug can extend the amount of time people with a subtype of glioma are on treatment without their cancer worsening. The finding suggests ...
Jun 5, 2023
0
70
St. Jude Children's Research Hospital is reporting phase 2 clinical trial results treating the brain tumor craniopharyngioma with proton therapy. The researchers found a similar survival rate between more targeted proton ...
Apr 19, 2023
0
46
Radiation kills tumors by creating oxygen free radicals that damage the tumor DNA. However, the lack of oxygen in the center of tumors blocks the production of free radicals, inhibiting radiation killing. NIBIB researchers ...
May 2, 2019
0
40
Newcastle University researchers have identified an antioxidant Tiron, which offers total protection against some types of sun damage and may ultimately help our skin stay looking younger for longer.
Jan 10, 2014
3
1
A new study led by researchers from the UCLA Health Jonsson Comprehensive Cancer Center shows that using high doses of radiation while integrating an ablative radiotherapy technique called stereotactic ablative radiotherapy ...
Jan 11, 2024
0
0
A new Phase Ib/II study from researchers at The University of Texas MD Anderson Cancer Center and Moffitt Cancer Center found that combining sensitizing drugs with a specific form of radiation therapy may be more effective ...
Nov 28, 2023
0
0
Repeat radiation therapy combined with the monoclonal antibody drug bevacizumab extended progression-free survival in patients with recurrent glioblastoma, according to findings from a recent clinical trial published in the ...
Apr 10, 2023
0
21
The Phase II results of the NRG Oncology HN004 trial indicate that radiotherapy (RT) with the PD-L1 inhibitor durvalumab did not improve progression-free survival (PFS) and led to significantly higher rates of locoregional ...
Oct 24, 2022
0
6
